Abstract

BackgroundMacrophage-Migration-Inhibitory-Factor (MIF) is a proinflammatory cytokine that has been demonstrated to be responsible of dysregulated apoptosis of fibroblasts in a variety of inflammatory-fibrotic diseases, including systemic sclerosis (SSc) (1). Moreover,...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Marked Expression of Macrophage Migration Inhibitory Factor in the Intrauterine Endometrium of Women With Endometriosis Varying With the Disease Stage, the Infertility Status and Pelvic Pain
A Akoum ... C.N Metz
Fertility and Sterility | VOL. 84
A Akoum, et. al.A Akoum ... C.N Metz
01 Sep 2005
Serum Levels of HCY, MIF, and hs-CRP Correlate with Glycolipid Metabolism in Adults with Never-Medicated First-Episode Schizophrenia.
Fei Xing ... Qin Ao
Evidence-based complementary and alternative medicine : eCAM | VOL. 2021
Fei Xing, et. al.Fei Xing ... Qin Ao
13 Nov 2021
Elevated serum levels of macrophage migration inhibitory factor and stem cell growth factor β in patients with idiopathic and systemic sclerosis associated pulmonary arterial hypertension.
G Valesini ... R Poscia
Reumatismo | VOL. 66
G Valesini, et. al.G Valesini ... R Poscia
31 Mar 2015
Expression of macrophage migration inhibitory factor and its receptor CD74 in systemic sclerosis.
Marisol Godínez-Rubí ... José Francisco Muñoz Valle
Central-European journal of immunology | VOL. 46
Marisol Godínez-Rubí, et. al.Marisol Godínez-Rubí ... José Francisco Muñoz Valle
01 Jan 2020
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers